In adult AML BM, increased inflammatory cytokine production (e.g. IL‐6, IL‐8, tumour necrosis factor α) led to JAK/STAT pathway activation, but monotherapy with a JAK/STAT inhibitor lacked substantial antileukaemic activity in vivo.14 The gene discussed is IL6; the disease is acute myeloid leukemia.